Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Jun
08
Today In Oncology
Teclistamab in Previously Treated Multiple Myeloma
Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
Sunvozertinib in NSCLC With EGFR Exon 20 Insertion Mutations
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo